ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 992,87
0,18%
Dow Jones
38 686,32
1,51%
DAX
18 497,94
-0,09%
Brent Oil
81,295
0,00%
Bitcoin
68 170,20
0,66%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Galapagos NV (GLPG)

  7. Galapagos NV (GLPG) Actualités

GLPG

Galapagos NV (GLPG)

Galapagos NV
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:GLPG
DateHeureSourceTitreSymboleSociété
30/05/202422h44Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLPGGalapagos NV
30/05/202422h01GlobeNewswire Inc.Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune’s TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indicationsNASDAQ:GLPGGalapagos NV
16/05/202422h01GlobeNewswire Inc.Galapagos creates new subscription right plansNASDAQ:GLPGGalapagos NV
15/05/202422h01GlobeNewswire Inc.Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos’ decentralized CAR-T manufacturing network in the U.S.NASDAQ:GLPGGalapagos NV
02/05/202422h01GlobeNewswire Inc.Galapagos reports first quarter 2024 financial results  NASDAQ:GLPGGalapagos NV
30/04/202422h01GlobeNewswire Inc.Galapagos’ shareholders adopt all resolutions proposed by the Board of Directors at the Annual and Extraordinary Shareholders Meetings 2024NASDAQ:GLPGGalapagos NV
04/04/202422h01GlobeNewswire Inc.Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024NASDAQ:GLPGGalapagos NV
28/03/202421h01GlobeNewswire Inc.Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ MeetingsNASDAQ:GLPGGalapagos NV
26/03/202421h01GlobeNewswire Inc.Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its BoardNASDAQ:GLPGGalapagos NV
22/02/202422h01GlobeNewswire Inc.Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Clinical-Stage PipelineNASDAQ:GLPGGalapagos NV
22/02/202422h01GlobeNewswire Inc.Galapagos announces full year 2023 results and outlook for 2024NASDAQ:GLPGGalapagos NV
15/02/202422h01GlobeNewswire Inc.Galapagos presents at EBMT-EHA annual meeting 2024NASDAQ:GLPGGalapagos NV
14/02/202423h41Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:GLPGGalapagos NV
31/01/202422h01GlobeNewswire Inc.Galapagos completes transaction to transfer Jyseleca® business to AlfasigmaNASDAQ:GLPGGalapagos NV
04/01/202422h44Dow Jones NewsGalapagos, Thermo Fisher to Collaborate on Expanding Manufacturing of Cancer DrugNASDAQ:GLPGGalapagos NV
04/01/202422h01GlobeNewswire Inc.Galapagos enters into strategic collaboration agreement with Thermo Fisher Scientific to further expand its decentralized CAR-T manufacturing network in the U.S.NASDAQ:GLPGGalapagos NV
03/01/202422h01GlobeNewswire Inc.Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncologyNASDAQ:GLPGGalapagos NV
03/01/202422h01PR Newswire (US)BridGene Biosciences Announces Strategic Collaboration with Galapagos to Discover Small Molecule Drugs for Oncology TargetsNASDAQ:GLPGGalapagos NV
02/01/202407h00GlobeNewswire Inc.Galapagos signs agreement to transfer Jyseleca® business to AlfasigmaNASDAQ:GLPGGalapagos NV
19/12/202322h01GlobeNewswire Inc.Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301NASDAQ:GLPGGalapagos NV
09/12/202318h00GlobeNewswire Inc.Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101NASDAQ:GLPGGalapagos NV
07/12/202322h01GlobeNewswire Inc.Galapagos to Host KOL Event on December 10, 2023, at 11:00 AM PST to discuss new data presented at ASH 2023NASDAQ:GLPGGalapagos NV
06/11/202313h45PR Newswire (US)Landmark Bio Signs Multi-Year Agreement to Manufacture Galapagos' Oncology CAR-T Cell Therapy Clinical Programs at the Point-of-CareNASDAQ:GLPGGalapagos NV
02/11/202321h01GlobeNewswire Inc.Galapagos reports third quarter 2023 results and releases new encouraging data from CAR-T studies for presentation at ASH 2023NASDAQ:GLPGGalapagos NV
30/10/202321h01GlobeNewswire Inc.Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca® business to AlfasigmaNASDAQ:GLPGGalapagos NV
19/09/202322h01GlobeNewswire Inc.Galapagos appoints Simon Sturge to its Board of DirectorsNASDAQ:GLPGGalapagos NV
28/08/202322h01GlobeNewswire Inc.Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus  NASDAQ:GLPGGalapagos NV
03/08/202322h01GlobeNewswire Inc.Galapagos announces first half-year 2023 financial resultsNASDAQ:GLPGGalapagos NV
15/06/202323h03Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:GLPGGalapagos NV
15/06/202322h01GlobeNewswire Inc.Galapagos appoints Thad Huston as Chief Financial Officer and Chief Operating OfficerNASDAQ:GLPGGalapagos NV
 Showing the most relevant articles for your search:NASDAQ:GLPG

Dernières Valeurs Consultées

LSE
40GQ
Montenegro 25a
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés